0000000000974626

AUTHOR

M Napolitano

showing 11 related works from this author

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct

Hypercoagulability during pregnancy: evidences for a thrombophilic state

2006

The development of thrombotic disorders is a major threat for young women during pregnancy. It is one of the main causes of pregnancy-related disorders, which may also result in harm for the conceptus. Successful pregnancies require an even balance of coagulation and fibrinolysis, in order to secure stabilization of the basal plate as well as adequate placental perfusion. Broad spectrum assays which measure a range of thrombin/fibrin formation in serum have become an established means of identifying activation of blood coagulation and/or fibrinolysis. There is considerable interest in the application of these assays to the diagnosis of other hypercoagulable states, such as thrombophilia dur…

PregnancyFibrinolysisPregnancy Complications HematologicFibrinolysiHumansThrombophiliaFemaleBlood CoagulationHuman
researchProduct

Search for K+ decays to a muon and invisible particles

2021

The NA62 experiment at CERN reports searches for $K^+\to\mu^+N$ and $K^+\to\mu^+\nu X$ decays, where $N$ and $X$ are massive invisible particles, using the 2016-2018 data set. The $N$ particle is assumed to be a heavy neutral lepton, and the results are expressed as upper limits of ${\cal O}(10^{-8})$ of the neutrino mixing parameter $|U_{\mu4}|^2$ for $N$ masses in the range 200-384 MeV/$c^2$ and lifetime exceeding 50 ns. The $X$ particle is considered a scalar or vector hidden sector mediator decaying to an invisible final state, and upper limits of the decay branching fraction for $X$ masses in the range 10-370 MeV/$c^2$ are reported for the first time, ranging from ${\cal O}(10^{-5})$ t…

Nuclear and High Energy PhysicsScalar (mathematics)FOS: Physical sciences01 natural sciences7. Clean energyNA62High Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciencesheavy neutral leptonsDark sector NA62physics beyond Standard Model010306 general physicsPhysicsRange (particle radiation)Muonkaon decays010308 nuclear & particles physicsBranching fractionDark sectorSettore FIS/04Kaonslcsh:QC1-999Hidden sectorParticleHigh Energy Physics::ExperimentNeutrinoParticle Physics - Experimentlcsh:PhysicsLepton
researchProduct

Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: …

2016

Background. Following high-dose chemotherapy/bone marrow transplantation, patients are routinely, prophylactically transfused with platelet concentrates (PC) if they have a platelet count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such transfusions are necessary in clinically stable patients with no bleeding, or whether a therapeutic transfusion strategy could be sufficient and safe, is still debated. Materials and methods. The GIMEMA Haemostasis and Thrombosis Working Party sent a questionnaire to Italian haematology departments to survey several aspects of daily platelet transfusion practice, such as the cut-off platelet count for transfusion, the e…

Settore MED/15 - MALATTIE DEL SANGUEBone marrow transplantationProphylaxisBleeding; Bone marrow transplantation; High-dose chemotherapy; Platelet transfusion; Prophylaxis; Immunology and Allergy; HematologyBleedingHigh-dose chemotherapybleeding platelet transfusion prophylaxis high-dose chemotherapy bone marrow transplantationImmunology and AllergyOriginal ArticleHematologyProphylaxiPlatelet transfusion
researchProduct

Inhibitors to factor VII in congenital factor VII deficiency.

2014

medicine.medical_specialtyPediatricsFactor VIIbusiness.industryInhibitorsFactor VII DeficiencyMEDLINErVIIaHematologyGeneral MedicineFactor VIIInhibitors Factor VII deficiencyGastroenterologyAntibodieschemistry.chemical_compoundchemistryInternal medicinerVIIa; FVII deficiency; InhibitorsmedicineHumansFVII deficiencyFactor VII deficiencybusinessGenetics (clinical)
researchProduct

Work environment, volume of activity and staffing in neonatal intensive care units in Italy: results of the SONAR-nurse study

2016

Background Neonatal units’ volume of activity, and other quantitative and qualitative variables, such as staffing, workload, work environment, care organization and geographical location, may influence the outcome of high risk newborns. Data about the distribution of these variables and their relationships among Italian neonatal units are lacking. Methods Between March 2010-April 2011, 63 neonatal intensive care units adhering to the Italian Neonatal Network participated in the SONAR Nurse study. Their main features and work environment were investigated by questionnaires compiled by the chief and by physicians and nurses of each unit. Twelve cross-sectional monthly-repeated surveys on diff…

Cross-sectional studyStaffingWorkloadCritical Care NursingPediatrics03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaNursing030225 pediatricsIntensive careCritical care nursingSurveys and QuestionnairesNeonatalIntensive Care Units NeonatalMedicineHumansSurveys and Questionnaire030212 general & internal medicineLocationWorkplaceCross-Sectional Studiebusiness.industryResearchNurse-Patient RelationInfant NewbornPatient AcuityInfantWorkloadPatient AcuityPerinatology and Child HealthNewbornInfant Newborn; Intensive Care Units Neonatal; Nurse-Patient Relations; Patient Acuity; Workload; Cross-Sectional Studies; Humans; Infant Newborn; Intensive Care Units Neonatal; Italy; Surveys and Questionnaires; Critical Care Nursing; Pediatric Nursing; Workload; WorkplacePediatric NursingInfant Newborn; Intensive Care Units Neonatal; Nurse-Patient Relations; Patient Acuity; WorkloadIntensive Care UnitsCross-Sectional StudiesItalyWorkforceInfant; Intensive care units; Neonatal; Newborn; Nurse-patient relations; Patient acuity; Workload; Cross-Sectional Studies; Humans; Infant Newborn; Intensive Care Units Neonatal; Italy; Surveys and Questionnaires; Critical Care Nursing; Pediatric Nursing; Workload; Workplace; Pediatrics Perinatology and Child HealthPediatric nursingbusinessNurse-Patient RelationsHuman
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolong…

2014

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect -

HeredityPharmacokinetic inherited Factor VII deficiencyFactor VII DeficiencySocio-culturaleFactor VIIaPharmacologySeverity of Illness IndexPharmacokineticsPredictive Value of Testshemic and lymphatic diseasesHumansMedicineGenetic Predisposition to DiseaseFVII deficiencyRegistriescardiovascular diseasesBlood CoagulationVolume of distributionbiologyCoagulantsbusiness.industryVascular biologyrFVIIaHematologyFactor VIIRecombinant ProteinsPhenotypeTreatment OutcomerFVIIa; FVII deficiency; pharmacokineticsRecombinant factor VIIaPharmacodynamicsbiology.proteinBlood Coagulation TestsSteady state (chemistry)Drug Monitoringbusinesspharmacokinetics
researchProduct

Proposal and validation of a novel quantitative approach (QUEM) for the evaluation of menstrual blood losses. Preliminary implementation for the mana…

2010

Menorrhagiaisaveryprevalentbleedingsymptomincongenitalbleedingdisorders(from60to100%)and in patients on OralAnticoagulants(OA),but no prospective studies are available. We here describe the validation of a new and simple method for determination of menstrual blòood losses

excessive menstrual blood losses determination of menses acquired coagulation disorders
researchProduct

The beam and detector of the NA62 experiment at CERN

2017

NA62 is a fixed-target experiment at the CERN SPS dedicated to measurements of rare kaon decays. Such measurements, like the branching fraction of the $K^{+} \rightarrow \pi^{+} \nu \bar\nu$ decay, have the potential to bring significant insights into new physics processes when comparison is made with precise theoretical predictions. For this purpose, innovative techniques have been developed, in particular, in the domain of low-mass tracking devices. Detector construction spanned several years from 2009 to 2014. The collaboration started detector commissioning in 2014 and will collect data until the end of 2018. The beam line and detector components are described together with their early …

Particle physicsPhysics - Instrumentation and DetectorsPhysics::Instrumentation and DetectorsFOS: Physical scienceslarge detector systems for particle and astroparticle physicsCalorimeters; Cherenkov detectors; Large detector systems for particle and astroparticle physics; Particle tracking detectors; Instrumentation; Mathematical PhysicsNA62 experimentTracking (particle physics)7. Clean energy01 natural sciencesParticle detectorHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNONuclear physicsmathematical physicsHigh Energy Physics - Experiment (hep-ex)Calorimeters0103 physical sciencesparticle tracking detectorsDetectors and Experimental Techniques010306 general physicsParticle Physicsphysics.ins-detCalorimeters; Cherenkov detectors; large detector systems for particle and astroparticle physics; particle tracking detectors; instrumentation; mathematical physicsPhysicsinstrumentationCalorimeterLarge Hadron Collider010308 nuclear & particles physicsBranching fractionhep-exDetectorCherenkov detectorsInstrumentation and Detectors (physics.ins-det)Particle tracking detectorBeamlineLarge detector systems for particle and astroparticle physicHigh Energy Physics::ExperimentBeam (structure)Particle Physics - ExperimentCherenkov detector
researchProduct

Kaon physics at the CERN-SPS

2015

The NA48/2 and NA62 collaborations report on recent results, current status, and prospects of kaon physics at the CERN-SPS. The NA62 collaborations aims to measure the decay [Formula: see text] with an uncertainty of 10% or better. The NA62 detector and preliminary results from a pilot run in 2014 are presented. In addition, recent results of the NA48/2 collaboration are reported. A search for Dark Photons has been performed in [Formula: see text] decays via the kaon decays [Formula: see text] and [Formula: see text]. No dark photon signal was observed and new upper limits on the mixing parameter [Formula: see text] and the dark photon mass were computed. We also report the first observati…

Nuclear physicsPhysicsParticle physicsLarge Hadron ColliderPhotonDetectorMeasure (physics)High Energy Physics::ExperimentMixing (physics)Dark photonSettore FIS/04 - Fisica Nucleare e Subnucleare
researchProduct